- Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drugThe second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts. Smaller biotechs are increasingly opting to launch their pr…
- Leqembi records best quarter since launch as Biogen raises guidanceLeqembi, the anti-amyloid Alzheimer’s drug from Eisai and Biogen, recorded $184 million in global sales in the second quarter, Biogen said Wednesday morning. It's the best showing for Leqembi since…Endpoints · 23m ago↗ source